drugset / Trial / NCT06686745
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
Phase 1
Recruiting
130 enrolled
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, first-in-human study to evaluate the safety,efficacy, and PK/PD characteristics of SIM0508 as a single agent and in combination with olaparib in participants with locally advanced/metastatic solid tumors.
Timeline
- Start
- 2024-12-06
- Primary completion
- 2027-06-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | — | — |
| Subject | SIM0508 | Unknown | — | — |